Canakinumab (CAN) plus docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results
No Thumbnail Available
Identifiers
Date
2021-09-21
Authors
Paz-Ares, L.
Goto, Y.
Lim, W. D. T.
Halmos, B.
Cho, B. C.
Dols, M. Cobo
Gonzalez-Larriba, J. L.
Zhou, C.
Demedts, I.
Atmaca, A.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
